To be the leading cGMP CRDMO globally in adherent bioprocessing/ continuous processing using flow chemistry utilizing our own in house proprietary/patented platforms and accelerate the discovery to delivery process of vaccines (human, animal, cancer), oncolytic viruses, cell/gene therapy, tissue engineering, mabs/recombinant proteins, diagnostics, small molecules, cosmeceuticals, peptides, biopolymers, bioscaffolds, and cosmetics/fast-moving consumer goods (FMCG).
We focus on offering vaccine-, bio-, cell- and gene-therapy development manufacturing services using primarily its proprietary Adherent Tide Motion Platform supplemented by single-use suspension and fermentation, downstream bioprocessing, and custom bioengineering equipment for client specific therapeutics.
Within the in vitro/in vivo Diagnostic space, we focus on developing mAb-based antigens, single-domain antibodies for radio imaging, RT PCR reagents, RCL diagnostics. We work with collaborators to provide turnkey mobile Dx labs: Aster Xpress™.
Within the chem- biopolymer- cosmetic, personal care, cosmeceutical segments, we excel in converting batch processes into continuous flow chemistry, closed aseptic processing within isolators and variety of skin safety/efficacy testing services.
For the COVID-19 pandemic we are working on an end-to-end trace, test, and treat platform from swab booths, to mobile labs, turnkey modular screening and treatment centres with isolation rooms as well as working on diagnostics, therapeutics, and vaccines.
We are driven to provide One Health-based measures, geared towards vaccination and less antibiotic dependence, to ensure animals considered as companions and nourishment providers, are free from diseases that transcends human and environmental health systems.
Esco Aster operates on dedicated sites based on our applications of our manufacturing platforms, each site has dedicated scientists working on specific modalities. Esco Aster will continue to scale up with our collaborators and partners for future commercial expansion in Singapore or as Internal Tech Transfer to client choice of country. Facilities and applications are:
Esco Aster Pte. Ltd.
#02-01, Blk 67 Ayer Rajah Crescent, Singapore 139950,
Esco AsterTide PD-Phase 2 CTM (Cells/Viruses/EVs)
#02-04 Blk 67 Ayer Rajah Crescent Singapore 139950
Esco AsterMavors Cellular Agriculture and Complementary Proteins (Food)
#03-20 Blk 71 Ayer Rajah Crescent Singapore 139951
Esco Aster's ISO 9001:2015 ensures that its business operations are robust and lays a quality management system foundation for the organization including its developmental sciences and services for Good Laboratory Practices (GLP)
Key potential benefits of possessing this standard include:
1990
Esco expanded distribution to pharmaceutical life science biotech and medical reserach markets
2007
Expansion of Esco life science and medical products
2006
Esco earned onsite Ul accreditation
2017
Esco Aster was introduced (first CRDMO company in Asia utilizing its own proprietary Tide Motion technology)
Esco Aster and Institute of Molecular Cell Biology announce a collaboration to accelerate pre-clinical development of a hand foot and mouth vaccine
Esco Aster and Bioprocessing Institute sign a Memorandum of Understanding to innovate on continuous manufacturing platform
2022
2023
Facility Expansion for Cultivated Meat Production
2021
Esco Aster received a food processing license to manufacture cell-based cultivated meat from Singapore Food Authority (SFA).
2019
Esco Aster continued to grow with the outfitting of a cGMP-compliant PD, GLP, Phase1 and 2 clinical trial facility.
2018
Esco Aster and
National University of Singapore announced a development of single-use bioreactor-based stem cells for bone regeneration.
2015
Esco VacciXcell was introduced
2001
Esco earned first EN 12469 cert. for BSC
1978
Esco was founded in Singapore and began to pioneer cleanroom technology in Southeast Asia
XL Lin founded and manages the Esco Aster and Esco Healthcare Division within the Esco Lifesciences Group in 2009 developing the companies' very first cGMP downflow/containment booths and isolation systems from concept development to sales, project management, site-work, and validation.
Under his leadership, Esco Pharma has expanded from just a small division to now having 3 factories globally in USA/UK and Singapore. He brings his unique skillset in social entrepreneurship, market development, strategic product development, globally alliance networking, sales/contract management, clean air/containment facility, and systems design/integration into Esco VacciXcell. XL Lin graduated with a Bachelor of Sciences from University of Sydney and he is currently pursuing various options for further studies.
